Healthcare Industry News: CARILLON
News Release - February 24, 2016
Carillon Mitral Contour System Associated with Significant Improvement of Functional Mitral RegurgitationKIRKLAND, Wash.--(Healthcare Sales & Marketing Network)--A single-center study recently published in the Journal of Invasive Cardiology noted that treatment with Cardiac Dimensions’ CARILLON® Mitral Contour System® resulted in significant improvement of functional (secondary) mitral regurgitation (FMR), a condition that can increase the symptoms of heart failure.
The CARILLON device is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely, utilizing standard interventional techniques. Through multiple clinical trials, the device has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life.
Researchers of the study noted that percutaneous treatment for FMR is clinically valuable1 due to the widespread prevalence of the problem and the lack of alternative available therapies.
“In this ‘real-life’ setting, we observed a marked reduction in FMR and continued improvement in the condition over time, with the majority of patients experiencing clinical success similar to the results of the TITAN Trial,” said Norbert Klein, M.D. University Hospital Leipzig, Department of Cardiology and Angiology and lead author of the study. “In addition, we experienced short procedure times, ease of implantation and compatibility with other cardiac therapies.”
Data were collected from a prospective, single-center, non-randomized observational analysis of 17 consecutive patients with moderate to severe FMR, despite stable optimal medical drug treatment. Patients were selected for percutaneous rather than surgical approach due to high surgical risk as assessed by EuroSCORE II and STS score.
About Cardiac Dimensions®
Cardiac Dimensions is a privately held medical device company that has developed the only right-sided, minimally invasive product specifically designed to treat functional (secondary) mitral regurgitation, or FMR. The company’s novel interventional technology, The CARILLON® Mitral Contour System®, is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely, utilizing standard interventional techniques. The implantable device consists of a distal anchor and a proximal anchor connected by a shaping ribbon and utilizes the heart’s venous anatomy to reshape the mitral annulus. This approach allows for reduction of the dilated annulus, addressing a root cause of functional mitral regurgitation (FMR). The CARILLON system has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life. In addition, all adjunctive treatment options remain available after placement of a CARILLON device, making it an ideal first-line therapy for FMR. The device is approved for use in Europe. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Offenbach, Germany. For more information, visit the company’s web site: http://www.cardiacdimensions.com.
CAUTION: The CARILLON® Mitral Contour System® is not approved for use in the United States.
Cardiac Dimensions, CARILLON and Mitral Contour System are registered trademarks of Cardiac Dimensions.
1Siminiak T, Wu JC, Haude M, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. European Journal of Heart Failure. Aug; 14(8): 931-938.
Source: Cardiac Dimensions
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.